Anaphylaxis After Immunization of Children and Adolescents in Germany.
Identifieur interne : 000109 ( Main/Exploration ); précédent : 000108; suivant : 000110Anaphylaxis After Immunization of Children and Adolescents in Germany.
Auteurs : Doris Oberle [Allemagne] ; Jutta Pavel ; Thorsten Rieck ; Stefan Weichert ; Horst Schroten ; Brigitte Keller-Stanislawski ; Tobias TenenbaumSource :
- The Pediatric infectious disease journal [ 1532-0987 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Allemagne (épidémiologie), Anaphylaxie (épidémiologie), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Hospitalisation (MeSH), Humains (MeSH), Immunisation (effets indésirables), Incidence (MeSH), Mâle (MeSH), Nourrisson (MeSH), Vaccins (administration et posologie), Vaccins (effets indésirables).
- MESH :
- administration et posologie : Vaccins.
- effets indésirables : Immunisation, Vaccins.
- épidémiologie : Allemagne, Anaphylaxie.
- Adolescent, Enfant, Enfant d'âge préscolaire, Femelle, Hospitalisation, Humains, Incidence, Mâle, Nourrisson.
English descriptors
- KwdEn :
- Adolescent (MeSH), Anaphylaxis (epidemiology), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Germany (epidemiology), Hospitalization (MeSH), Humans (MeSH), Immunization (adverse effects), Incidence (MeSH), Infant (MeSH), Male (MeSH), Vaccines (administration & dosage), Vaccines (adverse effects).
- MESH :
- chemical , administration & dosage : Vaccines.
- adverse effects : Immunization, Vaccines.
- epidemiology : Anaphylaxis, Germany.
- Adolescent, Child, Child, Preschool, Female, Hospitalization, Humans, Incidence, Infant, Male.
Abstract
BACKGROUND
Anaphylaxis is a life-threatening event. The aim of this study was to estimate the annual frequency of anaphylaxis after immunization in individuals younger than 18 years in Germany leading to hospitalization.
METHODS
All suspected cases of postvaccination anaphylaxis involving individuals aged 0-17 years reported to the German surveillance unit for rare pediatric diseases (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland) from June 2008 through May 2010, and all suspected cases of anaphylaxis as an adverse event following immunization in the same age group reported to the Paul-Ehrlich-Institut during the observational period were classified according to the Brighton collaboration case definition. Only hospitalized cases of anaphylaxis fulfilling Brighton collaboration case definition level 1-3 criteria were eligible. Estimates for the annual frequency were calculated by using capture-recapture methods.
RESULTS
A total of 22 reports were eligible. Median age of the affected individuals (13 males, 9 females) was 7.0 years (range: 2 months to 17 years). Anaphylaxis occurred most frequently after administration of AS03 adjuvanted A/H1N1 pandemic influenza vaccine (n = 8). The annual frequency of anaphylaxis after vaccination (excluding pandemic influenza vaccine as well as monovalent measles and rubella vaccines) was estimated to be 6.8 (95% confidence interval: 6.1-10.9). The estimated incidence of anaphylaxis after administration of specific vaccines ranged from 0.4 to 127.6 cases per 1,000,000 doses administered.
CONCLUSIONS
This study confirms that anaphylaxis after immunization in children and adolescents is a rare event. AS03 adjuvanted A/H1N1 pandemic influenza vaccine seems to be associated with a higher risk of anaphylaxis when compared with other vaccines.
DOI: 10.1097/INF.0000000000001073
PubMed: 26835973
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anaphylaxis After Immunization of Children and Adolescents in Germany.</title><author><name sortKey="Oberle, Doris" sort="Oberle, Doris" uniqKey="Oberle D" first="Doris" last="Oberle">Doris Oberle</name><affiliation wicri:level="1"><nlm:affiliation>From the *Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany; †Immunization Unit, Robert Koch Institute, Berlin, Germany; ‡Charité-University Medicine Berlin, Berlin, Germany; and §Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the *Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany; †Immunization Unit, Robert Koch Institute, Berlin, Germany; ‡Charité-University Medicine Berlin, Berlin, Germany; and §Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University</wicri:regionArea><wicri:noRegion>Heidelberg University</wicri:noRegion><wicri:noRegion>Heidelberg University</wicri:noRegion><wicri:noRegion>Heidelberg University</wicri:noRegion></affiliation></author><author><name sortKey="Pavel, Jutta" sort="Pavel, Jutta" uniqKey="Pavel J" first="Jutta" last="Pavel">Jutta Pavel</name></author><author><name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name></author><author><name sortKey="Weichert, Stefan" sort="Weichert, Stefan" uniqKey="Weichert S" first="Stefan" last="Weichert">Stefan Weichert</name></author><author><name sortKey="Schroten, Horst" sort="Schroten, Horst" uniqKey="Schroten H" first="Horst" last="Schroten">Horst Schroten</name></author><author><name sortKey="Keller Stanislawski, Brigitte" sort="Keller Stanislawski, Brigitte" uniqKey="Keller Stanislawski B" first="Brigitte" last="Keller-Stanislawski">Brigitte Keller-Stanislawski</name></author><author><name sortKey="Tenenbaum, Tobias" sort="Tenenbaum, Tobias" uniqKey="Tenenbaum T" first="Tobias" last="Tenenbaum">Tobias Tenenbaum</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26835973</idno><idno type="pmid">26835973</idno><idno type="doi">10.1097/INF.0000000000001073</idno><idno type="wicri:Area/Main/Corpus">000107</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000107</idno><idno type="wicri:Area/Main/Curation">000107</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000107</idno><idno type="wicri:Area/Main/Exploration">000107</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anaphylaxis After Immunization of Children and Adolescents in Germany.</title><author><name sortKey="Oberle, Doris" sort="Oberle, Doris" uniqKey="Oberle D" first="Doris" last="Oberle">Doris Oberle</name><affiliation wicri:level="1"><nlm:affiliation>From the *Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany; †Immunization Unit, Robert Koch Institute, Berlin, Germany; ‡Charité-University Medicine Berlin, Berlin, Germany; and §Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>From the *Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany; †Immunization Unit, Robert Koch Institute, Berlin, Germany; ‡Charité-University Medicine Berlin, Berlin, Germany; and §Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University</wicri:regionArea><wicri:noRegion>Heidelberg University</wicri:noRegion><wicri:noRegion>Heidelberg University</wicri:noRegion><wicri:noRegion>Heidelberg University</wicri:noRegion></affiliation></author><author><name sortKey="Pavel, Jutta" sort="Pavel, Jutta" uniqKey="Pavel J" first="Jutta" last="Pavel">Jutta Pavel</name></author><author><name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name></author><author><name sortKey="Weichert, Stefan" sort="Weichert, Stefan" uniqKey="Weichert S" first="Stefan" last="Weichert">Stefan Weichert</name></author><author><name sortKey="Schroten, Horst" sort="Schroten, Horst" uniqKey="Schroten H" first="Horst" last="Schroten">Horst Schroten</name></author><author><name sortKey="Keller Stanislawski, Brigitte" sort="Keller Stanislawski, Brigitte" uniqKey="Keller Stanislawski B" first="Brigitte" last="Keller-Stanislawski">Brigitte Keller-Stanislawski</name></author><author><name sortKey="Tenenbaum, Tobias" sort="Tenenbaum, Tobias" uniqKey="Tenenbaum T" first="Tobias" last="Tenenbaum">Tobias Tenenbaum</name></author></analytic><series><title level="j">The Pediatric infectious disease journal</title><idno type="eISSN">1532-0987</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Anaphylaxis (epidemiology)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Germany (epidemiology)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Immunization (adverse effects)</term><term>Incidence (MeSH)</term><term>Infant (MeSH)</term><term>Male (MeSH)</term><term>Vaccines (administration & dosage)</term><term>Vaccines (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Allemagne (épidémiologie)</term><term>Anaphylaxie (épidémiologie)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Immunisation (effets indésirables)</term><term>Incidence (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Vaccins (administration et posologie)</term><term>Vaccins (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunization</term><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunisation</term><term>Vaccins</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anaphylaxis</term><term>Germany</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Anaphylaxie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Hospitalization</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Incidence</term><term>Mâle</term><term>Nourrisson</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Anaphylaxis is a life-threatening event. The aim of this study was to estimate the annual frequency of anaphylaxis after immunization in individuals younger than 18 years in Germany leading to hospitalization.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>All suspected cases of postvaccination anaphylaxis involving individuals aged 0-17 years reported to the German surveillance unit for rare pediatric diseases (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland) from June 2008 through May 2010, and all suspected cases of anaphylaxis as an adverse event following immunization in the same age group reported to the Paul-Ehrlich-Institut during the observational period were classified according to the Brighton collaboration case definition. Only hospitalized cases of anaphylaxis fulfilling Brighton collaboration case definition level 1-3 criteria were eligible. Estimates for the annual frequency were calculated by using capture-recapture methods.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 22 reports were eligible. Median age of the affected individuals (13 males, 9 females) was 7.0 years (range: 2 months to 17 years). Anaphylaxis occurred most frequently after administration of AS03 adjuvanted A/H1N1 pandemic influenza vaccine (n = 8). The annual frequency of anaphylaxis after vaccination (excluding pandemic influenza vaccine as well as monovalent measles and rubella vaccines) was estimated to be 6.8 (95% confidence interval: 6.1-10.9). The estimated incidence of anaphylaxis after administration of specific vaccines ranged from 0.4 to 127.6 cases per 1,000,000 doses administered.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>This study confirms that anaphylaxis after immunization in children and adolescents is a rare event. AS03 adjuvanted A/H1N1 pandemic influenza vaccine seems to be associated with a higher risk of anaphylaxis when compared with other vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26835973</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0987</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>The Pediatric infectious disease journal</Title><ISOAbbreviation>Pediatr. Infect. Dis. J.</ISOAbbreviation></Journal><ArticleTitle>Anaphylaxis After Immunization of Children and Adolescents in Germany.</ArticleTitle><Pagination><MedlinePgn>535-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/INF.0000000000001073</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anaphylaxis is a life-threatening event. The aim of this study was to estimate the annual frequency of anaphylaxis after immunization in individuals younger than 18 years in Germany leading to hospitalization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All suspected cases of postvaccination anaphylaxis involving individuals aged 0-17 years reported to the German surveillance unit for rare pediatric diseases (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland) from June 2008 through May 2010, and all suspected cases of anaphylaxis as an adverse event following immunization in the same age group reported to the Paul-Ehrlich-Institut during the observational period were classified according to the Brighton collaboration case definition. Only hospitalized cases of anaphylaxis fulfilling Brighton collaboration case definition level 1-3 criteria were eligible. Estimates for the annual frequency were calculated by using capture-recapture methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 22 reports were eligible. Median age of the affected individuals (13 males, 9 females) was 7.0 years (range: 2 months to 17 years). Anaphylaxis occurred most frequently after administration of AS03 adjuvanted A/H1N1 pandemic influenza vaccine (n = 8). The annual frequency of anaphylaxis after vaccination (excluding pandemic influenza vaccine as well as monovalent measles and rubella vaccines) was estimated to be 6.8 (95% confidence interval: 6.1-10.9). The estimated incidence of anaphylaxis after administration of specific vaccines ranged from 0.4 to 127.6 cases per 1,000,000 doses administered.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms that anaphylaxis after immunization in children and adolescents is a rare event. AS03 adjuvanted A/H1N1 pandemic influenza vaccine seems to be associated with a higher risk of anaphylaxis when compared with other vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oberle</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the *Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany; †Immunization Unit, Robert Koch Institute, Berlin, Germany; ‡Charité-University Medicine Berlin, Berlin, Germany; and §Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavel</LastName><ForeName>Jutta</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rieck</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Weichert</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schroten</LastName><ForeName>Horst</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Keller-Stanislawski</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tenenbaum</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Infect Dis J</MedlineTA><NlmUniqueID>8701858</NlmUniqueID><ISSNLinking>0891-3668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000707" MajorTopicYN="N">Anaphylaxis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26835973</ArticleId><ArticleId IdType="doi">10.1097/INF.0000000000001073</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Keller Stanislawski, Brigitte" sort="Keller Stanislawski, Brigitte" uniqKey="Keller Stanislawski B" first="Brigitte" last="Keller-Stanislawski">Brigitte Keller-Stanislawski</name><name sortKey="Pavel, Jutta" sort="Pavel, Jutta" uniqKey="Pavel J" first="Jutta" last="Pavel">Jutta Pavel</name><name sortKey="Rieck, Thorsten" sort="Rieck, Thorsten" uniqKey="Rieck T" first="Thorsten" last="Rieck">Thorsten Rieck</name><name sortKey="Schroten, Horst" sort="Schroten, Horst" uniqKey="Schroten H" first="Horst" last="Schroten">Horst Schroten</name><name sortKey="Tenenbaum, Tobias" sort="Tenenbaum, Tobias" uniqKey="Tenenbaum T" first="Tobias" last="Tenenbaum">Tobias Tenenbaum</name><name sortKey="Weichert, Stefan" sort="Weichert, Stefan" uniqKey="Weichert S" first="Stefan" last="Weichert">Stefan Weichert</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Oberle, Doris" sort="Oberle, Doris" uniqKey="Oberle D" first="Doris" last="Oberle">Doris Oberle</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000109 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000109 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26835973
|texte= Anaphylaxis After Immunization of Children and Adolescents in Germany.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26835973" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |